Impact and economics of inclisiran in Switzerland
Research Project | 01.09.2020 - 31.12.2021
|
01.09.2020
- 31.12.2021
Funding
Impact and economics of inclisiran in Switzerland
Novartis Pharma Schweiz AG, 08.2020-05.2022 (22)
PI : Schwenkglenks, Matthias.
Publications
Galactionova, Katya et al. (2022) ‘Correction to: Cost-Effectiveness, Burden of Disease and Budget Impact of Inclisiran: Dynamic Cohort Modelling of a Real-World Population with Cardiovascular Disease.’, PharmacoEconomics, 40(8), p. 835. Available at: https://doi.org/10.1007/s40273-022-01171-5.
Galactionova, Katya et al. (2022) ‘Correction to: Cost-Effectiveness, Burden of Disease and Budget Impact of Inclisiran: Dynamic Cohort Modelling of a Real-World Population with Cardiovascular Disease.’, PharmacoEconomics, 40(8), p. 835. Available at: https://doi.org/10.1007/s40273-022-01171-5.
Galactionova, Katya et al. (2022) ‘Cost-Effectiveness, Burden of Disease and Budget Impact of Inclisiran: Dynamic Cohort Modelling of a Real-World Population with Cardiovascular Disease.’, PharmacoEconomics, 40(8), pp. 791–806. Available at: https://doi.org/10.1007/s40273-022-01152-8.
Galactionova, Katya et al. (2022) ‘Cost-Effectiveness, Burden of Disease and Budget Impact of Inclisiran: Dynamic Cohort Modelling of a Real-World Population with Cardiovascular Disease.’, PharmacoEconomics, 40(8), pp. 791–806. Available at: https://doi.org/10.1007/s40273-022-01152-8.
Members (1)
